Year: 2014
Type: article
Abstract: Summary. There is a growing gap in productivity in the biopharmaceutical industry. The money spent on developing new drugs has increased substantially, but the hoped-for dramatic increase in new therapies based on recent revolutions in molecular biology and genetics has yet to materialize. Long approval times, high-failures rates, and high-competition account in part for this situation. Some argue that entrepreneurs are not promoting fundamental, new discoveries and instead are simply profiting from the knowledge generated by academia. In fact, publicly funded research is driving progress in a completely new field and the development of a completely new landscape of medi-cine. The knowledge thereby acquired has dramatically changed the approach to targe-ting disease. In response, a new model is needed, one that addresses how investment in innovation is driven, but also how innovation is done. [Contrib Sci 10:29-34 (2014)] Correspondence:
Author: Mara Dierssen
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W1698140901